scholarly journals Cystatin C-based CKD-EPI Equations and N-Terminal Pro-B-Type Natriuretic Peptide for Predicting Outcomes in Acutely Decompensated Heart Failure

2015 ◽  
Vol 38 (2) ◽  
pp. 106-113 ◽  
Author(s):  
Pedro J. Flores-Blanco ◽  
Sergio Manzano-Fernández ◽  
Juan I. Pérez-Calvo ◽  
Francisco J. Pastor-Pérez ◽  
Francisco J. Ruiz-Ruiz ◽  
...  
Keyword(s):  
Heart Failure ◽  
Natriuretic Peptide ◽  
Cystatin C ◽  
Decompensated Heart Failure ◽  
Acutely Decompensated Heart Failure

Slight Worsening of Renal Function Occurs Even by Human Atrial Natriuretic Peptide in the Treatment of Acutely Decompensated Heart Failure

2005 ◽  
Vol 11 (9) ◽  
pp. S312
Author(s):  
Manabu Taneike ◽  
Kiyoshi Kume ◽  
Hideaki Kataiwa ◽  
Ken-Ichi Komukai ◽  
Noriko Sasaki ◽  
...  
Keyword(s):  
Heart Failure ◽  
Renal Function ◽  
Atrial Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Decompensated Heart Failure ◽  
Human Atrial Natriuretic Peptide ◽  
Acutely Decompensated Heart Failure ◽  
Atrial Natriuretic

scholarly journals Lowered B-Type Natriuretic Peptide in Response to Levosimendan or Dobutamine Treatment Is Associated With Improved Survival in Patients With Severe Acutely Decompensated Heart Failure

2009 ◽  
Vol 53 (25) ◽  
pp. 2343-2348 ◽  
Author(s):  
Alain Cohen-Solal ◽  
Damien Logeart ◽  
Bidan Huang ◽  
Danlin Cai ◽  
Markku S. Nieminen ◽  
...  
Keyword(s):  
Heart Failure ◽  
Natriuretic Peptide ◽  
Decompensated Heart Failure ◽  
Acutely Decompensated Heart Failure

Ularitide: a natriuretic peptide candidate for the treatment of acutely decompensated heart failure

2015 ◽  
Vol 11 (5) ◽  
pp. 531-546 ◽  
Author(s):  
Sitaramesh Emani ◽  
Markus Meyer ◽  
Denada Palm ◽  
Johannes Holzmeister ◽  
Garrie J Haas
Keyword(s):  
Heart Failure ◽  
Natriuretic Peptide ◽  
Decompensated Heart Failure ◽  
Acutely Decompensated Heart Failure ◽  
Peptide Candidate

Increased levels of cystatin-c are associated with hyponatremia in acutely decompensated heart failure patients with renal dysfunction

2013 ◽  
Vol 34 (suppl 1) ◽  
pp. P5734-P5734
Author(s):  
P. Rafouli-Stergiou ◽  
J. Parissis ◽  
V. Bistola ◽  
K. Vasiliadis ◽  
M. Nikolaou ◽  
...  
Keyword(s):  
Heart Failure ◽  
Renal Dysfunction ◽  
Cystatin C ◽  
Decompensated Heart Failure ◽  
Heart Failure Patients ◽  
Acutely Decompensated Heart Failure

The Characteristics of Patients with Acutely Decompensated Heart Failure Who are Difficult to Withdraw the Use of Natriuretic Peptide

2006 ◽  
Vol 12 (8) ◽  
pp. S173
Author(s):  
Kiyoshi Kume ◽  
Hideaki Kataiwa ◽  
Kenichi Komukai ◽  
Masaki Yamato ◽  
Noriko Sasaki ◽  
...  
Keyword(s):  
Heart Failure ◽  
Natriuretic Peptide ◽  
Decompensated Heart Failure ◽  
Acutely Decompensated Heart Failure

Prognostic value of in-hospital change in cystatin C in patients with acutely decompensated heart failure and renal dysfunction

2015 ◽  
Vol 182 ◽  
pp. 74-76 ◽  
Author(s):  
Pinelopi Rafouli-Stergiou ◽  
John Parissis ◽  
Dimitrios Farmakis ◽  
Vassiliki Bistola ◽  
Maria Nikolaou ◽  
...  
Keyword(s):  
Heart Failure ◽  
Renal Dysfunction ◽  
Cystatin C ◽  
Prognostic Value ◽  
Decompensated Heart Failure ◽  
Acutely Decompensated Heart Failure

Nesiritide: A Novel Approach for Acute Heart Failure

2003 ◽  
Vol 37 (2) ◽  
pp. 247-258 ◽  
Author(s):  
Aungkana Vichiendilokkul ◽  
Alison Tran ◽  
Eric Racine
Keyword(s):  
Heart Failure ◽  
Natriuretic Peptide ◽  
Randomized Clinical Trials ◽  
Clinical Symptoms ◽  
Drug Application ◽  
Common Adverse Effect ◽  
Decompensated Heart Failure ◽  
Medline Search ◽  
Acutely Decompensated Heart Failure ◽  
Venous Dilatation

OBJECTIVE: To review preclinical and clinical information related to nesiritide, a recombinant form of B-type natriuretic peptide approved for treatment of acutely decompensated heart failure. DATA SOURCES: Primary and review articles were identified by MEDLINE search (1966–May 2002) using the key words natriuretic peptide and heart failure, and through secondary sources. Natrecor's document submitted for the Food and Drug Administration (FDA) New Drug Application were obtained from the FDA Web site. STUDY SELECTION/DATA EXTRACTION: Peer-reviewed articles and abstracts of randomized clinical trials in humans were included in this review. DATA SYNTHESIS: Nesiritide has beneficial actions for treatment of heart failure, including arterial and venous dilatation, enhanced sodium and urinary excretion, and suppression of the renin–angiotensin–aldosterone and sympathetic nervous systems. It has been shown to improve hemodynamic parameters, primarily pulmonary capillary wedge pressure, as well as clinical symptoms in patients with acutely decompensated heart failure. Nesiritide produced more rapid hemodynamic improvement and caused significantly fewer adverse effects than intravenous nitroglycerin. The incidence of hypotension, the most common adverse effect, was comparable between nesiritide and nitroglycerin. Additionally, nesiritide is associated with a lower incidence of arrhythmias than dobutamine and has a neutral effect on mortality. CONCLUSIONS: Nesiritide offers an alternative for management of acutely decompensated heart failure. It is considered an option for patients who do not respond to other vasodilators, inotropes, or diuretics and for those at high risk of arrhythmias. Further pharmacoeconomic investigations for nesiritide are warranted.

Sign in / Sign up

Export Citation Format

Share Document